Sensei Biotherapeutics (NASDAQ:FTH) Reaches New 1-Year High – Here’s What Happened

Sensei Biotherapeutics, Inc. (NASDAQ:FTH) shares hit a new 52-week high on Wednesday . The stock traded as high as $37.97 and last traded at $38.61, with a volume of 124897 shares changing hands. The stock had previously closed at $34.51.

Wall Street Analyst Weigh In

FTH has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Sensei Biotherapeutics in a research note on Tuesday, August 11th. Wall Street Zen upgraded Sensei Biotherapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. BTIG Research reaffirmed a “buy” rating and set a $55.00 price target on shares of Sensei Biotherapeutics in a research report on Thursday, July 16th. Robert W. Baird assumed coverage on shares of Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 target price for the company. Finally, Weiss Ratings started coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $55.00.

Sensei Biotherapeutics Stock Performance

The company’s fifty day moving average price is $29.51. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -0.28 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, beating the consensus estimate of ($5.04) by $2.20. Equities analysts predict that Sensei Biotherapeutics, Inc. will post -13.18 EPS for the current year.

Insiders Place Their Bets

In other Sensei Biotherapeutics news, CFO Brian C. Stephenson purchased 9,391 shares of Sensei Biotherapeutics stock in a transaction that occurred on Wednesday, June 24th. The shares were bought at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the transaction, the chief financial officer owned 26,804 shares of the company’s stock, valued at approximately $700,388.52. This trade represents a 53.93% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Anand Kiran Parikh purchased 2,806 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were acquired at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the purchase, the chief executive officer owned 764,234 shares of the company’s stock, valued at $15,101,263.84. This represents a 0.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders purchased 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sensei Biotherapeutics

Large investors have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. purchased a new position in shares of Sensei Biotherapeutics in the 2nd quarter worth approximately $3,610,000. Renaissance Technologies LLC lifted its position in Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after buying an additional 20,525 shares during the last quarter. Stempoint Capital LP bought a new stake in Sensei Biotherapeutics in the first quarter worth $4,188,000. Vivo Capital LLC purchased a new position in Sensei Biotherapeutics during the first quarter worth $22,758,000. Finally, Citadel Advisors LLC bought a new position in Sensei Biotherapeutics during the second quarter valued at $307,000. 10.50% of the stock is owned by institutional investors.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.